The Needham biotech’s application for approval in the U.S. wasn’t greeted positively by investors, likely because it would be for a smaller patient population than hoped.
Source link
La Potencia Mas Caliente
The Needham biotech’s application for approval in the U.S. wasn’t greeted positively by investors, likely because it would be for a smaller patient population than hoped.
Source link